These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15613064)

  • 1. Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
    de Alvaro F; Velasco O; Honorato J; Calvo C; Parrondo I;
    Kidney Int Suppl; 2005 Jan; (93):S29-34. PubMed ID: 15613064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F; Bramlage P; Paar WD
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
    Bramlage P; Pittrow D; Kirch W
    Curr Med Res Opin; 2004 Oct; 20(10):1625-31. PubMed ID: 15462695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
    Andersen S; Bröchner-Mortensen J; Parving HH;
    Diabetes Care; 2003 Dec; 26(12):3296-302. PubMed ID: 14633817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
    Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
    Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
    Hosaka M; Inoue R; Satoh M; Watabe D; Hanazawa T; Ohkubo T; Asayama K; Obara T; Imai Y;
    Clin Exp Hypertens; 2018; 40(5):468-475. PubMed ID: 29172732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
    Palmer AJ; Annemans L; Roze S; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; De Alvaro F
    Kidney Int Suppl; 2005 Jan; (93):S52-4. PubMed ID: 15613069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
    Cetinkalp SS; Karadeniz MM; Erdogan MA; Ozgen GA; Yilmaz CO
    Saudi Med J; 2008 Oct; 29(10):1414-8. PubMed ID: 18946564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The KARTAN study: a postmarketing assessment of Irbesartan in patients with hypertension.
    Morales-Olivas FJ; Arístegui I; Estañ L; Rodicio JL; Moreno A; Gil V; Ferrón G; Velasco O;
    Clin Ther; 2004 Feb; 26(2):232-44. PubMed ID: 15038946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study.
    Ferrari P; Hess L; Pechere-Bertschi A; Muggli F; Burnier M
    J Hypertens; 2004 Jun; 22(6):1221-9. PubMed ID: 15167458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry].
    Tebbe U; Lüders S; de Haan F; Bramlage P; Böhm M; Thoenes M; Paar WD; Schrader J;
    Med Klin (Munich); 2007 Oct; 102(10):824-32. PubMed ID: 17928966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
    Sasso FC; Carbonara O; Persico M; Iafusco D; Salvatore T; D'Ambrosio R; Torella R; Cozzolino D
    Diabetes Care; 2002 Nov; 25(11):1909-13. PubMed ID: 12401731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.